Comparative cost-effectiveness of anticoagulation with bivalirudin or heparin with and without a glycoprotein IIb/IIIa-Receptor inhibitor in patients undergoing percutaneous coronary intervention in Sweden: A decision-analytic model

Clinical Therapeutics

Volumn 28, Issue 11, 2006, Pages 1947-1959

  Borg, Sixten ^a   Persson, Ulf ^a   Allikmets, Kristina ^b   Ericsson, Karin ^b  

^a SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^b Nycomed Denmark   (Denmark)

Author keywords

anticoagulation; cost effectiveness; percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG;

ADULT; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART INFARCTION; HUMAN; MALE; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; PROBABILITY; REVASCULARIZATION; STATISTICAL SIGNIFICANCE; SWEDEN; THERAPY EFFECT;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COST-BENEFIT ANALYSIS; DECISION MAKING; FEMALE; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; ISCHEMIA; MALE; MIDDLE AGED; MODELS, THEORETICAL; PEPTIDE FRAGMENTS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; SWEDEN;

EID: 33845967154     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.11.013     Document Type: Article

References (32)

1. Bertrand M.E., Simoons M.L., Fox K.A., et al., Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation [published corrections appear in Eur Heartj. 2003;24:485 and EurHeartJ. 2003;24:1174-1175]. Eur Heart J. 23 (2002) 1809-1840
2. Available at:. BCIS Audit Returns of Interventional Procedures. Accessed October 11, 2004 (2001). http://www.bcis.org.uk/resources/documents/Bcis01.ppt
3. Philipp R., and Grech E. Interventional pharmacotherapy. BMJ 327 (2003) 43-46
4. Wittkowsky A.K. The role ofthrombin inhibition during percutaneous coronary intervention. Pharmacotherapy 22 (2002) 97S-104S
5. Wiggins B.S., Spinler S., Wittkowsky A.K., and Stringer K.A. Bivalirudin: A direct thrombin inhibitor for percutaneous transluminal coronary angioplasty. Pharmacotherapy 22 (2002) 1007-1018
6. Cohen D.J., Lincoff A.M., Lavelle T.A., et al. Economic evaluation of bivalirudin with provisional glycoprotein Ilb/Illa inhibition versus heparin with routine glycoprotein Ilb/Illa inhibition for percutaneous coronary intervention: Results from the REPLACE-2 trial. J Am Coll Cardiol. 44 (2004) 1792-1800
7. Use of a monoclonal antibody directed against the platelet glycoprotein Ilb/Illa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med. 330 (1994) 956-961
8. Aguirre F.V., and Gill J.B. Increasing benefit, reducing risk: Focusing on hemorrhagic complications in percutaneous coronary intervention. J Invasive Cardiol. 14 Suppl B (2002) 48B-54B
9. Bittl J.A., Strony J., Brinker J.A., et al., Hirulog Angioplasty Study Investigators. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med. 333 (1995) 764-769
10. Bittl J.A., Chaitman B.R., Feit F., et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin in Angioplasty Study. Am Heart J. 142 (2001) 952-959
11. Lincoff A.M., Bittl J.A., Harrington R.A., et al., REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein Ilb/Illa blockade compared with heparin and planned glycoprotein Ilb/Illa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial [published correction appears in JAMA. 2003;289:1638]. JAMA 289 (2003) 853-863
12. Available at:. Swedish Council on Technology Assessment in Health Care. Report. Alert. Abciximab (ReoPro) in coronary artery disease. Accessed (April 2, 2004). http://www.www.sbu.seReport.aspReportlD=592langld=1typeld=3
13. The ESPRIT Investigators (Enhanced Suppression of the Platelet Ilb/Illa Receptor with Integrilin Therapy). Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial [published correction appears in Lancet. 2001;357: 1370]. Lancet 356 (2000) 2037-2044
14. The EPISTENT Investigators (Evaluation of Platelet Ilb/Illa Inhibitor for Stenting). Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety ofcoro nary stenting with use of platelet glycoprotein IIb/I I la blockade. Lancet 352 (1998) 87-92
15. Rao A.K., Pratt C., Berke A., et al. Thrombolysis in Myocardial Infarction (TIMI) trial-phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 11 (1988) 1-11
16. O'Sullivan A.K., Thompson D., and Drummond M.F. Collection of health-economic data alongside clinical trials: Is there a future for piggyback evaluations?. Value Health 8 (2005) 67-79
17. Hasdai D., Behar S., Wallentin L., et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J. 23 (2002) 1190-1201
18. Sales statistics, February 2005 [in Swedish] (2005), Läkemedelsstatistik AB, Stockholm, Sweden
19. Karvouni E., Katritsis D.G., and Ioannidis J.P. Intravenous glycoprotein Ilb/Illa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol. 41 (2003) 26-32
20. Statistical Y.o.S.2006 (2006), Statistics Sweden, Örebro, Sweden
21. Hartunian M.S., Smart C.N., and Thompson M.S. The Incidenceand Economic Costs of Major Health Impairments (1981), Lexington Books, Lexington, Mass
22. Lincoff A.M., Kleiman N.S., Kereiakes D.J., et al., REPLACE-2 Investigators. Long-term efficacy of bivalirudin and provisional glycoprotein Ilb/Illa blockade vs heparin and planned glycoprotein Ilb/Illa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial [published correction appears inJAMA. 2006,296:46]. JAMA 292 (2004) 696-703
23. Available at:. Prislathund-berdkna prisfördndringen sjaly (Consumer Price Index). Accessed (February 20, 2004). http://www.iaps.scb.se/KpiLathund/SiIverStream/Pages/pgBerakning.htm1
24. Farmacevtiska S.i.S.2006 (F.) (2006), Läkemedelsindustriföreningen, Stockholm, Sweden
25. Available at: http://www.svrn.org/priso04/7 91.pdf. Southern Regional Health Care Board. Prices and Reimbursements for the Southern Health Care Region. Accessed February 5, 2004 (2004)
26. Available at:. Joint Committee for the Medical Health Care Region Southeast Sweden. Fees for Services in the Health Care Region 2004 [in Swedish]. Accessed (February 5, 2004). http://www.e.lio.se/svn/Prislista/index.html
27. Available at:. The Northern County Councils Cooperation Committee. Regional List of Fees for the Northern Health Care Region, County Hospital Care and Primary Care, 2004 [in Swedish]. Accessed (February 5, 2004). http://www.norriandstingen.nu/2004_regpri.htm
28. Ghatnekar O., Persson U., Glader E.L., and Terent A. Cost of stroke in Sweden: An incidence estimate. Int J Technol Assess Health Care 20 (2004) 375-380
29. Briggs A.H. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17 (2000) 479-500
30. Available at:. SCAAR Swedish Coronary Angiography and Angioplasty Registry. Accessed April 2, 2004 (2002). http://www.socialstyrelsen.se/NR/rdonlyres/F9142904
31. The Swedish National Board of Health and Welfare's Guidelines for Cardiac Care 2004. Support for Decisions in Setting Priorities [in Swedish] (2004), National Board of Health and Welfare, Stockholm, Sweden
32. Aguirre F.V., Younis L.T., Chaitman B.R., et al. Early and 1-year clinical outcome of patients' evolving non-Q wave versus Q-wave myocardial infarction after thrombolysis. Results from the TIM I II study. Circulation 91 (1995) 2541-2548